Alzheimer's stocks are getting some play and are probably worth a
buy in 2015. From Alzheimer's Penny Stocks to Regular Alzheimer's Stocks, below is a list of some Top Alzheimer's Stocks
to do your research on. Alzheimer's is expected to triple by 2045 and several companies are working on key drugs to
try and solve the epidemic. While these Alzheimer's stocks are risky, they could offer a nice way to diversify
Alzheimer’s disease is a progressive, neurodegenerative disorder characterized by problems
with memory, thinking and behavior that eventually become severe enough to affect daily tasks. An estimated 5.3 million people
in the United States are currently living with Alzheimer’s disease. Alzheimer’s disease is the fifth leading cause
of death in the United States among those aged 65 and older and will be the underlying cause of death for more than 500,000
Americans in 2015.
Top Alzheimer's Stocks - Avanir Pharmaceuticals (AVNR) -
AVNR was my top Alzheimer's Disease stock last year but they were bought out for $17 for share. Now, a company called
Concert Pharmaceuticals (CNCE) has partned with Avanir and said this during the last conference call.
Avanir Pharmaceuticals intends to meet with the U.S. Food and Drug Administration
in early 2015 to discuss the potential advancement of AVP-786 into Phase 3 clinical testing for the treatment of agitation
in patients with Alzheimer’s Disease. In addition, Avanir is conducting a Phase 2 clinical trial evaluating AVP-786
for the treatment of major depressive disorder. Highlighted
broad clinical potential of AVP-786 under collaboration with Avanir Pharmaceuticals.
Concert Pharmaceuticals (CNCE) is now one of the best positioned
Alheimer's stocks going forward and shares have corrected to $15 from $18. Watch CNCE in 2015.
Best Alzheimer's Stocks 2015 - Acadia
Pharmaceuticals (ACAD) has been one of the one of the best drugs stocks over the last few years and the company has
a drug to potentially treat Alzheimer's.
Pimavanserin is also in Phase II development for Alzheimer’s
disease psychosis and has successfully completed a Phase II trial in schizophrenia. These may include treatment for psychoses
associated with other neurological disorders, including Alzheimer's disease.
The FDA has not approved any
drug to treat ADP. As symptoms progress and become more severe, physicians often resort to off-label use of antipsychotic
medications in ADP patients. Current antipsychotic drugs are associated with a number of side effects, which can be problematic
for elderly patients with Alzheimer's disease. In addition, antipsychotic drugs may exacerbate the cognitive disturbances
associated with Alzheimer's disease. Current antipsychotic drugs also have a black box warning for use in elderly patients
with dementia-related psychosis due to increased mortality and morbidity.
Alzheimers Stocks to Buy - Activis (ACT)/Forest Laboratories
Inc. (FRX) - Forest Laboratories Inc. (FRX) has an Alzheimers drug called Namenda which is designed to treat moderate
to severe cases of Alzheimers. The stock surged last year after the company sold to Acitivs (ACT) which Carl Icahn continue to be a big supporter of the company.
Forest Laboratories and Adamas Pharmaceuticals Announce Forest’s
Submission of New Drug Application for Memantine Extended Release and Donepezil Fixed-Dose Combination for Alzheimer’s
Forest Laboratories, Inc. (NYSE:FRX), a leading, fully integrated, specialty pharmaceutical company largely
focused on the United States market, and Adamas Pharmaceuticals Inc., a privately held specialty pharmaceutical company, announced
Forest’s submission of a New Drug Application (NDA) to the Food and Drug Administration for a fixed-dose combination
(FDC) of memantine HCl extended release (ER) and donepezil HCl for the treatment of moderate to severe dementia of the Alzheimer’s
“The concurrent use of memantine and donepezil is
a well-established treatment option for patients with moderate to severe dementia related to Alzheimer’s disease. Using
the two drugs together appears to provide benefit over using acetylcholinesterase inhibitors alone. Reducing the number of
pills by offering patients a fixed-dose combination helps lessen the daily medication burden and could improve patient adherence
and compliance,” said Pierre Tariot, MD, at the Banner Alzheimer’s Institute, who has also consulted to both Adamas
Alzheimer's Stocks to Watch - Here
are some more potential alzheimers stocks to watch. These companies have alzheimers drugs in the pipeline: Targacept,
Inc. (TRGT), Navidea Biopharmaceuticals, Inc (NAVB), Biogen Idec Inc. (BIIB), Transition Therapeutics Inc. (TTHI), Sangamo
Biosciences Inc. (SGMO), Ligand Pharmaceuticals Incorporated (LGND), Prana Biotechnology (PRAN)